Skip header and navigation

Narrow By

   MORE

9 records – page 1 of 1.

ACEi and ARBS in Hypertension and Heart Failure

https://libcat.nshealth.ca/en/permalink/provcat39106
Pasquale Perrone Filardi, editor. --Cham: Springer International Publishing : Imprint: Springer ; ISCP , c2015.
Available Online
View e-Book
Location
Online
This book summarizes how the renin angiotensin system is implicated in the progression of atherosclerotic disease as well as of left ventricular dysfunction and reviews the action of angiotensin converting enzyme inhibitors and AT1 receptor antagonists on reducing morbidity and mortality in patients with left ventricular dysfunction or in those at high cardiovascular risk with preserved ventricular function. ACEi and ARBS in Hypertension and Heart Failure is a highly practical reference reviewi…
Available Online
View e-Book
Other Authors
Perrone Filardi, Pasquale
Other Authors
International Society of Cardiovascular Pharmacotherapy
Responsibility
Pasquale Perrone Filardi, editor
Alternate Title
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in hypertension and heart failure
Place of Publication
Cham
Publisher
Springer International Publishing : Imprint: Springer ; ISCP
Date of Publication
c2015
Physical Description
1 online resource (x, 150 p. : 19 illus., 13 illus. in color)
Series Title
Current cardiovascular therapy
ISBN
9783319097886
9783319097879 (print ed.)
Subjects (MeSH)
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Heart Failure - drug therapy
Hypertension - drug therapy
Renin-Angiotensin System
Abstract
This book summarizes how the renin angiotensin system is implicated in the progression of atherosclerotic disease as well as of left ventricular dysfunction and reviews the action of angiotensin converting enzyme inhibitors and AT1 receptor antagonists on reducing morbidity and mortality in patients with left ventricular dysfunction or in those at high cardiovascular risk with preserved ventricular function. ACEi and ARBS in Hypertension and Heart Failure is a highly practical reference reviewing the evidence and providing a rationale for the appropriate use of RAS antagonists in cardiovascular diseases. It is written in an easy-to-follow format and with many illustrations to aid clarity and the assimilation of information. Each chapter is written by established authorities in their fields who are also experienced in explaining often complex concepts. The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner.
Contents
1. Angiotensin Converting Enzyme Inhibitors and AT1 Antagonists for Treatment of Hypertension -- 2. ACE Inhibitor and Renin–Angiotensin System the Cornerstone of Therapy for Systolic Heart Failure -- 3. Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System: Inhibitors in Patients with Hypertension and Heart Failure -- 4. Target Organ Damage and RAAS Blockade.
Format
e-Book
Location
Online
Less detail

Antiplatelet and anticoagulation therapy

https://libcat.nshealth.ca/en/permalink/provcat32336
Albert Ferro, David A. Garcia, editors. --London: Springer , c2013.
Available Online
View e-Book
Location
Online
Aspirin has been in clinical use for over 100 years, making it one of the oldest commonly used drugs in medicine, and is now predominantly used as an antiplatelet agent. Major new antiplatelet drug classes have recently become available for the clinician that offer the promise of major improvements in the treatment and prevention of arterial thrombotic disease. In the field of anticoagulation, the vitamin K antagonists such as warfarin have not been available for as long as aspirin in the antip…
Available Online
View e-Book
Other Authors
Ferro, Albert
Garcia, David A
Responsibility
Albert Ferro, David A. Garcia, editors
Place of Publication
London
Publisher
Springer
Date of Publication
c2013
Physical Description
1 online resource (x, 247 p. : 37 ill., 26 ill. in color)
Series Title
Current cardiovascular therapy
ISBN
9781447142973
Subjects (MeSH)
Arterial Occlusive Diseases - drug therapy
Blood Coagulation Factor Inhibitors - therapeutic use
Platelet Aggregation Inhibitors - therapeutic use
Thrombosis - drug therapy
Subjects (LCSH)
Cardiology
Abstract
Aspirin has been in clinical use for over 100 years, making it one of the oldest commonly used drugs in medicine, and is now predominantly used as an antiplatelet agent. Major new antiplatelet drug classes have recently become available for the clinician that offer the promise of major improvements in the treatment and prevention of arterial thrombotic disease. In the field of anticoagulation, the vitamin K antagonists such as warfarin have not been available for as long as aspirin in the antiplatelet field, and have also had very little in the way of competition until recently; although a number of parenteral anticoagulants have been available, the vitamin K antagonists have been the only orally active anticoagulant drugs. The last few years have seen the arrival of new drug classes, the orally active direct thrombin inhibitors and factor Xa antagonists, which offer a number of advantages, but not without important drawbacks. In the face of these important advances in both antiplatelet and anticoagulant therapy, clinicians often feel confused, even overwhelmed, as to what is now available and which drugs are useful (and indicated) in which circumstances. Antiplatelet and Anticoagulant Therapy is designed with such people in mind. It is written in an easy-to-follow format and with many illustrations to aid clarity and the assimilation of information. Each chapter is written by established authorities in their fields who are also experienced in explaining often complex concepts. The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner.
Contents
Antiplatelet agents: current and novel -- Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring -- Anticoagulant Drugs: Current and Novel -- Antithrombotic Treatment of Cardiovascular Disease -- Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease -- Index.
Format
e-Book
Location
Online
Less detail

Atrial fibrillation therapy

https://libcat.nshealth.ca/en/permalink/provcat33699
Gheorghe-Andrei Dan, Antoni Bayés de Luna, John Camm, editors. --London: Springer , c2014.
Available Online
View e-Book
Location
Online
The paradigm for atrial fibrillation (AF) management has changed significantly in recent years. A new era has begun for the prevention of one of the most tremendous complication of AF, stroke. Prevention of ischemic stroke in AF patients with oral anticoagulants represents a huge challenge because of the narrow therapeutic change of these drugs, interindividual and intraindividual variability, and the unsatisfactory time in therapeutically range (TTR) with this type of medication.
Available Online
View e-Book
Corporate Author
International Society of Cardiovascular Pharmacotherapy
Other Authors
Dan, G. Andrei
Bayés de Luna, Antoni
Camm, A. John
Responsibility
Gheorghe-Andrei Dan, Antoni Bayés de Luna, John Camm, editors
Place of Publication
London
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (xiv, 188 pages)
Series Title
Current cardiovascular therapy
ISBN
9781447154754 (electronic bk.)
9781447154747
Subjects (MeSH)
Atrial Fibrillation - drug therapy
Subjects (LCSH)
Atrial fibrillation
Cardiology
Abstract
The paradigm for atrial fibrillation (AF) management has changed significantly in recent years. A new era has begun for the prevention of one of the most tremendous complication of AF, stroke. Prevention of ischemic stroke in AF patients with oral anticoagulants represents a huge challenge because of the narrow therapeutic change of these drugs, interindividual and intraindividual variability, and the unsatisfactory time in therapeutically range (TTR) with this type of medication.
Contents
Epidemiology, burden and unmet needs in atrial fibrillation -- Inside molecular mechanisms and pharmacological targets of atrial fibrillation -- Novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation -- Upstream therapy in the treatment of atrial fibrillation -- Drug therapy for rhythm and rate control in atrial fibrillation -- Changing the paradigm to understand and manage atrial fibrillation -- Guidelines and current recommendations in atrial fibrillation.
Format
e-Book
Location
Online
Less detail

Cardiac drugs in pregnancy

https://libcat.nshealth.ca/en/permalink/provcat33787
Karen Sliwa, John Anthony, editors. --London: Springer ; ISCP , c2014.
Available Online
View e-Book
Location
Online
In the western world, the risk of cardiovascular disease in pregnancy has grown due to the increasing age at the first pregnancy and the worldwide obesity epidemic leading to early diabetes and hypertension. As a result more women are requiring drug therapy during pregnancy and some data has shown an altered pharmacodynamic profile in pregnant women when compared to the non-pregnant population. Cardiac Drugs in Pregnancy presents up-to-date research for the treatment of cardiovascular disease d…
Available Online
View e-Book
Corporate Author
International Society of Cardiovascular Pharmacotherapy
Other Authors
Sliwa, Karen
Anthony, John
Responsibility
Karen Sliwa, John Anthony, editors
Place of Publication
London
Publisher
Springer ; ISCP
Date of Publication
c2014
Physical Description
1 online resource (xii, 131 pages)
Series Title
Current cardiovascular therapy
ISBN
9781447154723 (electronic bk.)
9781447154716
Subjects (MeSH)
Cardiovascular Agents - therapeutic use
Pregnancy Complications, Cardiovascular - drug therapy
Pregnancy
Subjects (LCSH)
Obstetrical pharmacology
Cardiovascular agents
Cardiovascular diseases in pregnancy
Cardiology
Obstetrics/Perinatology
Maternal and Child Health
Pharmacotherapy
Abstract
In the western world, the risk of cardiovascular disease in pregnancy has grown due to the increasing age at the first pregnancy and the worldwide obesity epidemic leading to early diabetes and hypertension. As a result more women are requiring drug therapy during pregnancy and some data has shown an altered pharmacodynamic profile in pregnant women when compared to the non-pregnant population. Cardiac Drugs in Pregnancy presents up-to-date research for the treatment of cardiovascular disease during pregnancy, and discusses the most important indications of drug usage in pregnancy and postpartum. The book aims to assess the potential risk of drugs and their possible benefit against each other, making it an essential read for a wide range of health professionals involved in cardiac drug therapy in pregnancy.
Contents
General principles and guidelines -- Management of hypertension -- Management of heart failure pre- and postpartum -- Management of coronary artery disease and arrhythmias -- Anticoagulation in pregnancy -- Obstetric drugs in the management of cardiovascular disease.
Format
e-Book
Location
Online
Less detail

Pharmacological treatment of acute coronary syndromes

https://libcat.nshealth.ca/en/permalink/provcat33393
Pablo Avanzas, Peter Clemmensen, editors. --London: Springer ; ISCP , c2014.
Available Online
View e-Book
Location
Online
Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and…
Available Online
View e-Book
Corporate Author
International Society of Cardiovascular Pharmacotherapy
Other Authors
Avanzas, Pablo
Clemmensen, Peter
Responsibility
Pablo Avanzas, Peter Clemmensen, editors
Place of Publication
London
Publisher
Springer ; ISCP
Date of Publication
c2014
Physical Description
1 online resource (xvi, 245 pages)
Series Title
Current cardiovascular therapy
ISBN
9781447154242 (electronic bk.)
9781447154235
Subjects (MeSH)
Acute Coronary Syndrome - drug therapy
Anticoagulants - therapeutic use
Platelet Aggregation Inhibitors - therapeutic use
Subjects (LCSH)
Cardiovascular pharmacology
Heart - Diseases - Chemotherapy
Coronary heart disease
Electrocardiography
Pharmacology
Acute coronary syndrome - Diagnosis
Abstract
Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs.
Contents
1. Anti-ischemic Therapy -- 2. Antiaggregant Therapy: New potent P2Y12 inhibitors -- 3. Anticoagulation Therapy: Heparins and Factor Xa inhibitors -- 4. Secondary prevention in ACS: The role of novel oral anticoagulants -- 5. American versus European guidelines: Critical appraisal -- 6. Triple therapy: Risky but sometimes necessary -- 7. Management of bleeding complications.
Format
e-Book
Location
Online
Less detail

Pharmacological Treatment of Chronic Stable Angina Pectoris

https://libcat.nshealth.ca/en/permalink/provcat39277
Pablo Avanzas, Juan Carlos Kaski, editors. --Cham: Springer , c2015.
Available Online
View e-Book
Location
Online
This book describes the clinical challenge currently posed by stable angina pectoris and provides guidance for those making clinical decisions regarding its pharmacological treatment. The importance of providing effective treatment is beyond dispute and this book deals with the most relevant aspects related to its pharmacological treatment. The pathogenesis of myocardial ischemia as the basis for rational treatment of angina is discussed thoroughly together with all major management goals inclu…
Available Online
View e-Book
Other Authors
Avanzas, Pablo
Kaski, Juan Carlos
Responsibility
Pablo Avanzas, Juan Carlos Kaski, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2015
Physical Description
1 online resource (xi, 278 p. : 32 illus., 23 illus. in color)
Series Title
Current cardiovascular therapy
ISBN
9783319173320
9783319173313 (print ed.)
Subjects (MeSH)
Adrenergic beta-Antagonists - therapeutic use
Angina Pectoris - drug therapy
Cardiovascular Agents - therapeutic use
Abstract
This book describes the clinical challenge currently posed by stable angina pectoris and provides guidance for those making clinical decisions regarding its pharmacological treatment. The importance of providing effective treatment is beyond dispute and this book deals with the most relevant aspects related to its pharmacological treatment. The pathogenesis of myocardial ischemia as the basis for rational treatment of angina is discussed thoroughly together with all major management goals including optimal symptom control and the secondary prevention of serious cardiovascular events. Pharmacological Treatment of Chronic Stable Angina Pectoris provides a clear description of the mechanisms of action and clinical indications of available anti-angina drugs and strategies for the use of novel pharmacological agents. It also includes a critical appraisal of the major management guidelines, which will assist the reader to interpret current evidence and provide the most appropriate forms of treatment. The ongoing controversy regarding medical therapy versus myocardial revascularization for the management of stable angina pectoris is also addressed. This eminently practical book will help guide the reader through the complexities of the field and will be highly appreciated by clinicians, clinical cardiologists and cardiology trainees alike.
Contents
Mechanisms of angina pectoris -- An overview of treatment and guidelines: ESC/ACC-AHA/NICE -- Beta-blockers -- Calcium channel blockers -- Nitrates -- Nicorandil -- Ivabradine -- Trimetazidine -- Ranolazine -- New antianginal drugs still not available for clinical use -- Medical therapy versus revascularization in the management of stable angina pectoris.
Format
e-Book
Location
Online
Less detail

Pharmacologic Trends of Heart Failure

https://libcat.nshealth.ca/en/permalink/provcat40173
Hector O. Ventura, editor. --Cham: Springer , c2016.
Available Online
View e-Book
Location
Online
This volume reviews potential future therapies for heart failure, with a particular focus on ambulatory acute decompensated heart failure and the transitions from therapies in the acute setting to chronic management. Although in the developed world the incidence of and mortality from coronary heart disease and stroke have been declining over the last 15 years, heart failure is increasing in incidence, prevalence and overall mortality, despite advances in the diagnosis and management of the cond…
Available Online
View e-Book
Other Authors
Ventura, Hector O
Responsibility
Hector O. Ventura, editor
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2016
Physical Description
1 online resource (vii, 173 p. : 8 illus., 6 illus. in color)
Series Title
Current cardiovascular therapy
ISBN
9783319305936
9783319305912 (print ed.)
Subjects (MeSH)
Drug Design
Heart Failure - drug therapy
Technology, Pharmaceutical - trends
Abstract
This volume reviews potential future therapies for heart failure, with a particular focus on ambulatory acute decompensated heart failure and the transitions from therapies in the acute setting to chronic management. Although in the developed world the incidence of and mortality from coronary heart disease and stroke have been declining over the last 15 years, heart failure is increasing in incidence, prevalence and overall mortality, despite advances in the diagnosis and management of the condition. Pharmacologic Trends of Heart Failure builds on the current understanding of pathophysiological mechanisms and insights gained from previous studies of therapeutic interventions. It is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis.
Contents
The Established Therapies: HF-PEF and HF-REF -- Novel Therapies for the Prevention and Management of Acute Decompensated Heart Failure -- A Comprehensive Transition of Care Plan For a Patient Admitted with Acute Decompensated Heart Failure -- Volume Assessment and Management: Medical and Device Therapies.
Format
e-Book
Location
Online
Less detail

Pharmacotherapy in Aortic Disease

https://libcat.nshealth.ca/en/permalink/provcat39103
Arturo Evangelista, Christoph A. Nienaber, editors. --Cham: Springer , c2015.
Available Online
View e-Book
Location
Online
This book is driven by the considerable progress made by novel imaging techniques in understanding the pathophysiology and evolution of aortic disease and its diagnosis. Despite the lack of symptoms in stable conditions, most aortic diseases have a high morbidity and mortality. New therapeutic strategies such as endovascular treatment and surgical techniques have appeared to improve conventional surgery in advanced phases of the disease, but until recently, medical treatment has focused on the …
Available Online
View e-Book
Other Authors
Evangelista, Arturo
Nienaber, Christoph A
Responsibility
Arturo Evangelista, Christoph A. Nienaber, editors
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2015
Physical Description
1 online resource (xii, 269 p. : 31 illus., 23 illus. in color)
Series Title
Current cardiovascular therapy
ISBN
9783319095554
9783319095547 (print ed.)
Subjects (MeSH)
Aortic Diseases - drug therapy
Abstract
This book is driven by the considerable progress made by novel imaging techniques in understanding the pathophysiology and evolution of aortic disease and its diagnosis. Despite the lack of symptoms in stable conditions, most aortic diseases have a high morbidity and mortality. New therapeutic strategies such as endovascular treatment and surgical techniques have appeared to improve conventional surgery in advanced phases of the disease, but until recently, medical treatment has focused on the control of cardiovascular risk factors using beta-blockers to reduce aortic wall stress by reducing blood pressure and heart rate. Pharmacotherapy in Aortic Disease updates the reader on the new medical treatments that are changing the natural history of these diseases. Leading experts have created a critical in-depth, yet concise, analysis of the available medical treatments for different aortic disease entities. Both basic research studies and clinical trials discussed in this book serve as a base for improving therapeutic management, delaying the need for surgery, and prolonging survival in these patients.
Contents
Aortic atherosclerosis as an embolic source -- Aortitis -- Pharmacotherapy of Thoracic Aortic aneurysm -- Marfan Syndrome -- Acute Aortic Syndrome: Medical Management -- Medical Treatment in Chronic aortic dissection.
Format
e-Book
Location
Online
Less detail

Treatment of Pulmonary Hypertension

https://libcat.nshealth.ca/en/permalink/provcat39164
Brendan Madden, editor. (1st ed.) --Cham: Springer , c2015.
Available Online
View e-Book
Location
Online
This book offers highly practical information on pharmaceutical options in pulmonary hypertension and is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. Treatment of Pulmonary Hypertension allows readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs. The emphasis is on current practice, but with an eye to the near-future dire…
Available Online
View e-Book
Other Authors
Madden, Brendan
Responsibility
Brendan Madden, editor
Edition
1st ed.
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2015
Physical Description
1 online resource (vii, 182 p. : 14 illus., 9 illus. in color)
Series Title
Current cardiovascular therapy
ISBN
9783319135816
9783319135809 (print ed.)
Subjects (MeSH)
Hypertension, Pulmonary - drug therapy
Hypertension, Pulmonary - surgery
Abstract
This book offers highly practical information on pharmaceutical options in pulmonary hypertension and is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. Treatment of Pulmonary Hypertension allows readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs. The emphasis is on current practice, but with an eye to the near-future direction of treatment. Written in a quick-access, no-nonsense format and with an emphasis on a just-the-facts clinical approach, this book will be of value to trainees, recertifying physicians, practicing physicians and other professional staff in internal medicine, cardiology, emergency medicine, thrombosis, hematology, pathology, and clinical pharmacology.
Contents
1. The Pathophysiology, Presentation and Diagnostic Investigation of Pulmonary Hypertension -- 2. Molecular Biological Aspects, Therapeutic Targets and New Treatment Strategies -- 3. Current Treatment Strategies, Guidelines and New Therapies -- 4. The Role of Surgery in Pulmonary Hypertension -- 5. Putting It All Together.
Format
e-Book
Location
Online
Less detail

9 records – page 1 of 1.